Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Guidelines
  3. ESMO-MCBS
  4. ESMO-MCBS for Solid Tumours

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines approved by the European Medicines Agency and the US Food and Drug Administration that have been scored and published by ESMO.

ESMO-MCBS scores are based on peer reviewed clinical trial reports. They are generated using a validated standard methodology and are reviewed by a team of clinicians and statisticians before publication. ESMO-MCBS scores should be interpreted in the context of an evolving treatment landscape, in connection with clinical practice guidelines.

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 22
4 136
3 161
2 55
1 24
NEB 4
Curative setting
A 59
C 3
NEB 3
ESMO-MCBS Scores by tumour type
Non-curative setting
Brain Tumours 4
Breast Cancer 39
Endocrine Tumours 23
Gastrointestinal Cancers 76
Genitourinary Cancers 71
Gynaecological Malignancies 38
Head and neck cancer 12
Non-cancerous soft-tissue tumour 3
Sarcoma 14
Skin Cancers 29
Thoracic Malignancies 86
TMB-H solid tumours 1
Tumour agnostic 6
Curative setting
Brain Tumours 2
Breast Cancer 9
Endocrine Tumours 0
Gastrointestinal Cancers 17
Genitourinary Cancers 5
Gynaecological Malignancies 1
Head and neck cancer 1
Non-cancerous soft-tissue tumour 0
Sarcoma 3
Skin Cancers 14
Thoracic Malignancies 13
TMB-H solid tumours 0
Tumour agnostic 0

The ESMO-MCBS Scorecards

reset selection
Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR.
To evaluate ESMO-MCBS score adjustments based on quality of life .

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Therapeutic Indication Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Relugolix - Leuprolide Treatment of adult patients with advanced HSPC HERO
    Genitourinary Cancers
    		 Prostate cancer - HERO

    4

    PRELIMINARY SCORE

    • NI

    ADJUSTMENTS

    SCORE

    • F2c
      4
    Nivolumab + ipilimumab - ChT First-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥1% CheckMate 648
    Gastrointestinal Cancers
    		 Oesophageal squamous cell carcinoma PD-L1 expression ≥1% CheckMate 648

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Nivolumab - Placebo Monotherapy for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) with tumour cell PD-L1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of MIUC. CheckMate 274
    Genitourinary Cancers
    		 Urothelial Carcinoma PD-L1 expression ≥1% CheckMate 274

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Nivolumab - Placebo Adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence after undergoing radical resection CheckMate 274
    Genitourinary Cancers
    		 Urothelial Carcinoma - CheckMate 274

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Nivolumab Fluoropyrimidine + platinum-based combination ChT ChT First-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥1% CheckMate 648
    Gastrointestinal Cancers
    		 Oesophageal squamous cell carcinoma PD-L1 expression ≥1% CheckMate 648

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Pembrolizumab - Single arm Adult and pediatric patients with recurrent, locally advanced or metastatic Merkel cell carcinoma KEYNOTE-017
    Skin Cancers
    		 Merkel cell carcinoma - KEYNOTE-017

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Pembrolizumab - Ipilimumab Treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma KEYNOTE-006
    Skin Cancers
    		 Cutaneous Melanoma - KEYNOTE-006

    A

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a/F1
      4

      A
    Sorafenib - Placebo Treatment of HCC SHARP
    Gastrointestinal Cancers
    		 Hepatobiliary Cancers - Hepatocellular Carcinoma - SHARP

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    177Lu-PSMA-617 Best standard of care (restricted) Best standard of care (restricted) In combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane based chemotherapy. VISION
    Genitourinary Cancers
    		 Prostate cancer PSMA-positive mCRPC VISION

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      5
    Relatlimab Nivolumab Nivolumab Treatment of adult and paediatric patients 12 years of age or older with unresectable or metastatic melanoma RELATIVITY-047
    Skin Cancers
    		 Cutaneous Melanoma - RELATIVITY-047

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Olaparib - Placebo Adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant ChT OlympiA
    Breast Cancer
    		 Early Breast Cancer gBRCAm HER2-negative OlympiA

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Pembrolizumab - Single arm Treatment of adults with MSI-H or dMMR unresectable or mCRC after previous fluoropyrimidine-based combination therapy KEYNOTE-164
    Gastrointestinal Cancers
    		 Colorectal Cancer dMMR or MSI-H KEYNOTE-164

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Pembrolizumab - Single arm cohort study Treatment of MSI-H or dMMR tumours in adults with unresectable or metastatic gastric cancer, who have disease progression on or following at least one prior therapy KEYNOTE-158
    Gastrointestinal Cancers
    		 Gastric Cancer dMMR or MSI-H KEYNOTE-158

    2

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      2
    Pembrolizumab - Single arm cohort study (Phase II) Treatment of MSI-H or dMMR tumours in adults with unresectable or metastatic small intestine cancer, who have disease progression on or following at least one prior therapy. KEYNOTE-158
    Gastrointestinal Cancers
    		 Small intestine dMMR or MSI-H KEYNOTE-158

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Pembrolizumab - Single arm cohort study (Phase II) Treatment of MSI-H or dMMR tumours in adults with unresectable or metastatic biliary cancer, who have disease progression on or following at least one prior therapy. KEYNOTE-158
    Gastrointestinal Cancers
    		 Biliary tract cancer dMMR or MSI-H KEYNOTE-158

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Pembrolizumab Lenvatinib Treatment of physician's choice (doxorubicin or paclitaxel) Patients with advanced or recurrent endometrial carcinoma who have progressed following prior platinum-containing therapy in any setting and who are not candidates for curative surgery or RT KEYNOTE-775
    Gynaecological Malignancies
    		 Endometrial Cancer - KEYNOTE-775

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Pembrolizumab Lenvatinib Treatment of physician's choice (doxorubicin or paclitaxel) Patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy and are not candidates for curative surgery or RT KEYNOTE-775
    Gynaecological Malignancies
    		 Endometrial Cancer - KEYNOTE-775

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.